Published in Women's Health Weekly, March 9th, 2006
"Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) are both commonly used assays for evaluation of HER-2/neu status in breast cancer," pathologists in the United States explained. "However, there is still no consensus on which method is most predictive of patient response to Herceptin."
"Recently, the automated cellular imaging system (ACIS) has been shown to improve the accuracy and reproducibility in scoring IHC," noted O.W. Tawfik and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly